Biotech News
GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion
Prefilled syringe offers a convenient ready-to-use administration option to healthcare professionals.
Related news
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST
BioCryst to Present at Upcoming Investor Conference
CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST
Coherus to Participate in Upcoming Investor Conferences
CRSPCRISPR Therapeutics2026-09-08 12:30 EST
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
NTLAIntellia2026-09-04 12:00 EST
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
KRYSKrystal Biotech2026-09-03 12:00 EST
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference
REPLReplimune Group2026-09-03 12:00 EST
Replimune to Present at the Cantor Global Healthcare Conference 2026
EXELExelixis2026-09-01 20:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
LEGNLegend Biotech Corporation2026-09-01 12:00 EST
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-09-15 14:21 EST
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences
GSKGSK plc2026-09-13 19:30 EST
GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer
GSKGSK plc2026-09-13 08:00 EST
Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
GSKGSK plc2026-09-10 07:00 EST
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japan
GSKGSK plc2026-09-01 07:00 EST
GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data
Stock data
- Close
- 51.08 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States